Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.
The concentrations of moxifloxacin achieved after a single 400 mg dose were measured in serum, epithelial lining fluid (ELF), alveolar macrophages (AM) and bronchial mucosa (BM). Concentrations were determined using a microbiological assay. Nineteen patients undergoing fibre-optic bronchoscopy were studied. Mean serum, ELF, AM and BM concentrations at 2.2, 12 and 24 h were as follows: 2.2 h: 3.2 mg/L, 20.7 mg/L, 56.7 mg/L, 5.4 mg/kg; 12 h: 1.1 mg/L, 5.9 mg/L, 54.1 mg/L, 2.0 mg/kg; 24 h: 0.5 mg/L, 3.6 mg/L, 35.9 mg/L, 1.1 mg/kg, respectively. These concentrations exceed the MIC(90)s for common respiratory pathogens such as Streptococcus pneumoniae (0.25 mg/L), Haemophilus influenzae (0.03 mg/L), Moraxella catarrhalis (0.12 mg/L), Chlamydia pneumoniae (0.12 mg/L) and Mycoplasma pneumoniae (0. 12 mg/L) and indicate that moxifloxacin should be effective in the treatment of community-acquired, lower respiratory tract infections.
Soman
A
A
Department of Thoracic Medicine, City Hospital, Birmingham, UK. Department of Medical Microbiology, City Hospital, Birmingham, UK.
Honeybourne
D
D
Andrews
J
J
Jevons
G
G
Wise
R
R
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019072:Antibiotic Prophylaxis; D001372:Aza Compounds; D001826:Body Fluids / Q000737:chemistry; D001980:Bronchi / Q000737:chemistry; D001999:Bronchoscopy; D004848:Epithelium / Q000502:physiology; D005260:Female; D005336:Fiber Optic Technology; D024841:Fluoroquinolones; D006801:Humans; D016676:Macrophages, Alveolar / Q000737:chemistry; D008297:Male; D000077266:Moxifloxacin; D011804:Quinolines; D020545:Respiratory Mucosa / Q000737:chemistry
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin